

## LIST OF FIGURES

<b>Figure No.</b>	<b>Title</b>
Figure 2.1	Praziquantel
Figure 4.1	Standard calibration curve for PZQ
Figure 4.2	HPLC analytical chromatogram of praziquantel
Figure 4.3(a)	FT-IR of pure $\beta$ -CD
Figure 4.3(b)	FT-IR of $\beta$ -CD Nanosponges
Figure 4.3(c)	FT-IR of pure PZQ
Figure 4.3(d)	FT-IR of PZQ-NS
Figure 4.4	DSC thermograms of PZQ, Physical Mixture and Drug NS complex
Figure 4.5(a)	XRD spectra of $\beta$ - CD
Figure 4.5(b)	XRD spectra of $\beta$ - CD Nanosponges
Figure 4.5(c)	XRD spectra of PZQ
Figure 4.5(d)	XRD spectra of PZQ loaded NS
Figure 4.6	SEM of (a) NS; (b) PZQ loaded NS
Figure 4.7	TEM of (a) NS; (b) PZQ loaded NS
Figure.4.8	Dissolution profiles of PZQ and PZQ-NS in (a) 0.1 N HCl and (b) phosphate buffer pH 6.8
Figure 4.9	HPLC chromatogram for praziquantel
Figure 4.10	Calibration curve for praziquantel

Figure.4.11	Plasma concentration time profile of PZQ suspension and PZQ-NS in rats
Figure 5.1	Partition behaviour of Praziquantel in different lipids
Figure 5.2	Effect of homogenization time on particle size of SLN
Figure 5.3	Effect of sonication time on particle size of SLN
Figure 5.4	Effect of Volume of formulation on particle size of SLN
Figure 5.5	Effect of lipophilic surfactant concentration on particle size of SLN
Figure 5.6	Effect of lipophilic surfactant concentration on Entrapment Efficiency of SLN
Figure 5.7	Effect of hydrophilic surfactant concentration on particle size of SLN
Figure 5.8	Effect of hydrophilic surfactant concentration on Entrapment Efficiency of SLN
Figure 5.9	Effect of lipid concentration on particle size of SLN
Figure 5.10	Effect of lipid concentration on EE of SLN
Figure 5.11	Effect of drug concentration on particle size of SLN
Figure 5.12	Effect of drug concentration on EE of SLN
Figure 5.13	Effect of lipid type on particle size of SLN
Figure 5.14	Effect of lipid type on EE of SLN
Figure 5.15	Effect of surfactant type on particle size of SLN
Figure 5.16	Effect of surfactant type on EE of SLN

- Figure 5.17 *In vitro* release studies in different time intervals of PZQ-loaded SLN in 0.1N HCl (pH 1.2) as dialysis medium
- Figure 5.18 *In vitro* release studies in different time intervals of PZQ-loaded SLN in phosphate buffer (pH 6.8) as dialysis medium
- Figure 5.19 Transmission electron micrographs (TEM) of different solid lipid nanoparticles. (A) Blank PZQ SLN ,(B) PZQ TM-SLN,(C) PZQ TP-SLN and (D) PZQ TS-SLN
- Figure 5.20 DSC thermograms of (A)Praziquantel, (B)Trimyristin, (C)Praziquantel loaded TM -SLN, (D)Tripalmitin, (E) Praziquantel loaded TP-SLN (F)Tristearin (G) Praziquantel loaded TS-SLN .
- Figure 5.21 XRD patterns of (A)Praziquantel, (B)Trimyristin, (C)Praziquantel loaded TM -SLN, (D)Tripalmitin, (E) Praziquantel loaded TP-SLN (F)Tristearin (G) Praziquantel loaded TS-SLN and (H)Drug free SLN.
- Figure 6.1: *In vitro* release studies in different time intervals of PZQ-loaded BSLN in 0.1N HCl (pH 1.2) as dialysis medium
- Figure 6.2 *In vitro* release studies in different time intervals of PZQ-BSLN in Phosphate buffer (pH 6.8) as dialysis medium
- Figure 6.3 Transmission electron micrographs (TEM) of PZQ-BSLN
- Figure 6.4 DSC thermograms of (A) Praziquantel, (B) Glycerol monostearate, (C) Tripalmitin, (D) Praziquantel loaded BSLN.
- Figure 6.5 Overlapped XRD patterns of (A) Praziquantel(PZQ), (B) Glycerol monostearate (GMS), (C) Tripalmitin (TP),(D) Praziquantel loaded GMS-SLN,(E) Praziquantel loaded TP-SLN, (F) Praziquantel loaded binary SLN(TP:GMS:75:25).

- Figure 7.1 The mean plasma concentration–time curve after single oral administration of PZQ-SLN, PZQ-BSLN and PZQ suspension (0.5% w/v Methyl Cellulose suspension of pure PZQ) in rats (50 mg /kg)
- Figure 7.2 The mean plasma concentration–time curve after single subcutaneous administration of PZQ-SLN, PZQ-BSLN and PZQ suspension (0.5% w/v Methyl Cellulose suspension of pure PZQ) in rats (50 mg /kg).
- Figure 7.3 The mean plasma concentration–time curve after a single intramuscular administration of PZQ-SLNs and PZQ suspension(0.5% w/v Methyl Cellulose suspension of pure PZQ) in rats (50 mg /kg)
- Figure 7.4 The mean plasma concentration–time curve after single intraduodenal administration of PZQ-SLN and PZQ BSLN (50 mg /kg) in rats treated with saline or cycloheximidine
- Figure 8.1 *In vitro* delivery of PZQ from PZQ BSLN and PZQ suspension (0.5% w/v methyl cellulose suspension of pure PZQ) through hydatid cyst membrane.
- Figure 8.2 Scanning Electron Microscopy of *E. granulosus* protoscoleces (A) Control protoscoleces, (B) Protoscoleces incubated *in vitro* with PZQ SLN (0.5 µg/ml), (C-D) Protoscoleces incubated *in vitro* with PZQ BSLN (0.5 µg/ml).
- Figure 8.3 Light microscopy of *E.granulosus* protoscoleces. (A) Control protoscoleces, (B-D) Protoscoleces incubated *in vitro* with PZQ SLN (PLN, 0.5 µg/ml).

Figure 8.4

Comparative protoscolocidal activity of PZQ-SLN and PZQ-BSLN with respect to PZQ suspension